The functional roles and mechanisms of polyamines in age-related bone diseases Authors: Jiaqiang Zhang, Chang Cai, Yifan Zhang, Cheng Luo, Shicheng Huo, Kun Wang, Changgui Shi, Jia Liu, Guohua Xu Published: 2025 ABSTRACT AbstractAge-related bone diseases such as osteoporosis, osteoarthritis, and sarcopenia present complex pathogenesis. These conditions are associated with high morbidity, disability, and mortality rates, underscoring the urgent need for effective prevention and treatment strategies. Polyamines, a group of small-molecule compounds, regulate critical biological processes, including cell proliferation, differentiation, and apoptosis, and show potential bone-protective effects. Following the elucidation of polyamines’ therapeutic effects in cancer and neurodegenerative diseases, growing research attention has been directed toward their role in age-related bone disorders. This review synthesizes the current understanding of polyamines’ mechanisms in age-related bone diseases, analyzing their biological functions and bone-protective effects to explore the therapeutic potential for these conditions, thereby offering valuable perspectives to guide future investigations and clinical applications in this emerging field.Supplementary InformationThe online version contains supplementary material available at 10.1007/s00018-025-06001-3.Keywords: Polyamine, Bone disease, Osteoporosis, Osteoarthritis, Sarcopenia, Bone metabolism, Spermine, Spermidine Introduction The global rise in aging populations has precipitated an increased prevalence of age-related bone disorders, such as osteoporosis and osteoarthritis, posing a substantial challenge to public health systems worldwide. Postmenopausal osteoporosis results in fractures in approximately 50% of affected women [1], while osteoarthritis, a leading cause of chronic disability, impacts over 500 million individuals globally [2]. These conditions not only severely compromise the quality of life of the elderly but also impose profound socioeconomic burdens [3–5]. The core features of skeletal aging include dysregulated bone metabolism, deterioration of bone microstructure, degeneration of articular cartilage, and compromised biomechanical properties. These manifestations arise from a complex interplay of multifactorial mechanisms: (1) cellular senescence, notably in osteoblasts and chondrocytes; (2) epigenetic dysregulation, encompassing aberrant DNA methylation and histone modifications; (3) mitochondrial dysfunction, leading to redox imbalance and metabolic perturbations; and (4) a pro-inflammatory microenvironment fueled by persistent cytokine signaling [6–11]. Current therapies, such as anti-resorptive agents, NSAIDs, and arthroplasty, can only temporarily relieve symptoms but fail to halt disease progression or restore compromised bone microarchitecture [12–14]. To address these therapeutic shortcomings, deciphering the molecular mechanisms of bone aging and developing targeted interventions has become a pivotal strategy [15, 16]. In recent years, the modulation of polyamine metabolism has emerged as a promising therapeutic strategy in oncology and neurology, sparking growing interest in its potential role in bone homeostasis. Accumulating evidence now implicates polyamines as critical regulators in the aging skeleton, influencing key pathophysiological processes. This review comprehensively synthesizes current knowledge on the mechanistic involvement of polyamines in age-related bone diseases, critically appraises recent research advances, and explores their translational potential as novel therapeutic targets to counteract bone aging and improve patient outcomes. Polyamines: molecules with multiple functions Polyamines, primarily comprising putrescine (PUT), spermidine (SPD), and spermine (SPM), are low-molecular-weight, polycationic alkylamines that are ubiquitously present in mammalian cells at millimolar concentrations. These molecules are integral to a multitude of fundamental cellular processes governing growth and survival, including: (1) the synthesis of proteins and nucleic acids; (2) the stabilization of chromatin structure; (3) the regulation of cell differentiation and apoptosis; (4) protection against oxidative stress; (5) facilitation of DNA repair; and (6) modulation of intercellular communication [17] (Table 1). The intracellular homeostasis of polyamines is tightly regulated and intimately interconnected with nucleotide, amino acid, and lipid metabolism [23]. The polyamine biosynthetic pathway initiates with the conversion of ornithine to PUT, catalyzed by ornithine decarboxylase (ODC). Subsequently, S-adenosylmethionine decarboxylase (AMD1) generates decarboxylated S-adenosylmethionine (dcSAM), which serves as an aminopropyl donor. Spermidine synthase (SRM) then catalyzes the addition of an aminopropyl group to PUT, forming SPD, which is in turn converted to SPM by spermine synthase (SMS) through the transfer of a second aminopropyl group [24–26]. The activities of the rate-limiting enzymes ODC and AMD1 are meticulously controlled at transcriptional, translational, and post-translational levels to maintain polyamine equilibrium [27]. Cells degrade or excrete polyamines mainly through spermidine/spermine N1-acetyltransferase 1 (SSAT) and peroxisomal acetylpolyamine oxidase (PAOX). Alternatively, spermine oxidase (SMOX) can directly convert SPM to SPD [28] (Fig. 1). Table 1Brief introductions of three types of polyamines Brief introductions of three types of polyamines Schematic diagram of intestinal polyamine uptake, metabolism, and their effects on osteoarthritis, osteoporosis, and sarcopenia. Most intestinal lumen polyamines are passively absorbed into the systemic circulation via the proximal small intestine, while others undergo active transport into IECs. Intracellular polyamine synthesis begins with ODC-catalyzed conversion of ornithine to PUT, followed by its sequential conversion to SPD and SPM. Polyamine catabolism and excretion primarily involve SSAT and PAOX, though SPM can also be directly metabolized to SPD via SMOX. Circulating polyamines and their metabolites are systemically distributed and exert therapeutic effects through distinct pathways: (1) Via the gut-joint axis, they alleviate cartilage inflammation and oxidative stress while suppressing ECM degradation in chondrocytes, mitigating OA progression; (2) Through the gut-bone axis, they enhance osteogenesis and inhibit bone resorption to combat osteoporosis; (3) By modulating the gut-muscle axis, they regulate muscle cell autophagy pathways to influence sarcopenia development. IEC: intestinal epithelial cell, OB: osteoblast, OC: osteoclast Beyond their intracellular roles, polyamines are also abundant extracellularly. A significant portion of the body’s polyamine pool is derived from the gastrointestinal tract, sourced from the diet, gut microbiota, and endogenous secretions. Luminal polyamines, present at high concentrations, can enter systemic circulation to support cellular growth. Mammalian cells employ two principal pathways for polyamine uptake: direct transport across the plasma membrane via specific permeases into polyamine sequestration vesicles (PSVs), or receptor-mediated endocytosis. Following sequestration into PSVs, polyamines are released into the cytosol; this critical step is mediated by P5B-type ATPases—specifically, ATP13A2 and ATP13A3—which utilize ATP hydrolysis to drive polyamine efflux from the vesicular lumen into the cytoplasm [21, 29]. This process not only facilitates cytosolic polyamine acquisition but also contributes to the fine-tuning of intracellular levels through enhanced endocytic cycling [30]. ATP13A2 and ATP13A3 exhibit distinct subcellular localizations and substrate preferences: ATP13A2, resident in late endosomes/lysosomes, shows a higher affinity for SPM, whereas ATP13A3, located in early/recycling endosomes, preferentially transports PUT [21]. Additionally, the vacuolar H+-ATPase SLC18B1 has been implicated in the storage and release of SPD and SPM within secretory cells [31]. Notably, the pronounced upregulation of SLC18B1 in the lysosomal vesicles of inflammation-activated macrophages suggests a potential link between lysosomal polyamine transport and the established anti-inflammatory and immunosuppressive properties of polyamines [32]. Polyamines are indispensable for normal cellular proliferation, and their depletion invariably triggers cell cycle arrest. Consequently, dysregulation of polyamine metabolism is implicated in the pathogenesis of a diverse spectrum of diseases, including cancer, neurological disorders, cardiovascular and metabolic diseases, immune/inflammatory conditions, and age-related bone disorders [18–20, 22, 33–37]. This recognition has spurred the rapid expansion of polyamine-targeted therapeutic strategies. The irreversible ODC inhibitor α-difluoromethylornithine (DFMO), for instance, is an FDA-approved agent for African trypanosomiasis, hirsutism, and neuroblastoma [38–41], and is currently under investigation for colorectal cancer chemoprevention, diabetes, and Snyder-Robinson syndrome [42–46]. Beyond DFMO, a growing arsenal of strategies—including natural polyamine supplements, polyamine analogs, and polyamine transport inhibitors—has demonstrated considerable therapeutic potential across various conditions [47–49]. Mounting evidence particularly underscores that an imbalance in polyamine metabolism is a key contributor to the process of bone aging [50–52]. In light of these findings, this review will critically focus on elucidating the potential of therapeutic strategies that modulate polyamine metabolism for the treatment of age-related bone disorders. Polyamine functions in age-related bone diseases Osteoporosis Osteoporosis, a prevalent age-related metabolic bone disease, arises from an imbalance between osteoclast-mediated bone resorption and osteoblast-mediated bone formation. This dysregulation leads to reduced bone mass, microarchitectural deterioration, and a consequent increase in bone fragility and fracture risk [53, 54]. The disease typically progresses asymptomatically [55], driven by three pathological processes: loss of trabecular bone, persistent net resorption at endosteal surfaces, and declining cortical volumetric bone mineral density (vBMD). Trabecular bone loss initiates in early adulthood (21–49 years) via mechanisms that remain incompletely understood. Notably, sexual dimorphism is evident in this process: women predominantly exhibit a reduction in trabecular number, whereas men show a decrease in trabecular thickness [56]. With advancing age and declining sex hormone levels, endosteal resorption intensifies, leading to pathological trabeculation of cortical bone, manifested as cortical thinning and increased porosity. Collectively, these changes drive an annual vBMD decline of 1.2–1.8%, significantly compromising bone strength and fracture resistance [57] (Table 2). Table 2The functional roles and mechanisms of polyamines in age-related bone diseasesPolyamine typeDisease/ModelMechanism/HypothesisMain FindingsReferencesSpermidine- ACLT or TNF-α-induced mice- Human FLS cells- Regulates deubiquitination of RIP1 in FLS- Inhibition of TNF-α/NF-κB pathway- Relieves synovitis, cartilage degeneration, osteophyte formation, and OA progression [58]Spermidine- DMM-induced mice- Primary human chondrocytes- Inhibition of ERK/MAPK and p65/NF-κB signaling pathways- Reduces degeneration of articular cartilage- Promotes transformation of macrophages from M1 to M2 subtype [59]Spermidine- ACLT-induced Rats- IL-1β-induced chondrocytes- Inhibition of AhR/NF-κB and NLRP3/caspase-1/GSDMD signaling pathways- Inhibition of inflammation, pyroptosis, and ECM degradation [60]Spermidine- ACLT-induced mice- Cell line- Activation of Nrf2/KEAP1 signaling pathway and inhibition of STAT3 phosphorylation;- Reverse the down-regulation of BRG1 (chromatin remodeling factor) in cartilage of OA mice- Enhances Antioxidant and anti-inflammatory effects [61]Spermidine- Primary human chondrocytes- Induction of mitophagy and inhibition of NF-κB activation- Reduces oxidative stress, and inflammatory response- Increase autophagy flux [62]Spermidine- Chondrocytes from OA patients- Mouse chondrocytes- Up-regulation of acetyltransferase EP300, autophagy activation- Slow down aging, OA-related cartilage degeneration, and pro-inflammatory factors [63]Spermidine; Spermine- OVX-treated mice- Inhibition of osteoclast function and promote osteogenic function.- Promote periosteal bone formation [64]Spermine- Fast-twitch muscle-specific AR knockout mice- Sex differential regulation of the androgen-polyamine metabolic axis and AR signaling pathway- Reduces male fmARKO mice trabecular and cortical BMD [65]Spermine- SmsG56S/0 mice- Energy metabolism and oxidative stress may be involved in the regulation of osteogenic phenotype- Increases trabecular bone volume, cortical thickness, the rate of bone formation, and the ability of mineralization [66]Putrescine;Spermidine; Spermine- Primary mouse osteoclast precursor cells- Inhibition of the Ca2+-PYK2-Src-NFATc1 signaling axis- Inhibition of osteoclast precursor cell migration and osteoclastogenesis [67]Polyamine metabolite- Cell line- Inhibition of RANK-NFATc1 signaling pathway- Inhibition of osteoclast formation [68]Spermidine; spermine- OVX-treated rats/Cell line- Inhibition of RANK-NFATc1 signaling pathway- Reduces osteoclast activity- Increases bone volume and trabecular thickness of femur [69]Spermidine- Col6a1-null mice- Modulation of the AKT-FOXO axis in skeletal muscle- Inhibition of muscle atrophy- Promotes the histological and ultrastructural integrity, and muscles strength [70]Spermidine- Mice- EP300-mediated autophagy and the ACVR2B/Smads signaling pathway- Promotes satellite cell activation and muscle atrophy [71]Spermidine; spermine- Sarcopenia patients- Lower SPM/SPD ratio in Sarcopenia patients- SPM/SPD ratio may serve as an indicative biomarker for sarcopenia [72] The functional roles and mechanisms of polyamines in age-related bone diseases - ACLT or TNF-α-induced mice - Human FLS cells - Regulates deubiquitination of RIP1 in FLS - Inhibition of TNF-α/NF-κB pathway - DMM-induced mice - Primary human chondrocytes - Reduces degeneration of articular cartilage - Promotes transformation of macrophages from M1 to M2 subtype - ACLT-induced Rats - IL-1β-induced chondrocytes - ACLT-induced mice - Cell line - Activation of Nrf2/KEAP1 signaling pathway and inhibition of STAT3 phosphorylation; - Reverse the down-regulation of BRG1 (chromatin remodeling factor) in cartilage of OA mice - Reduces oxidative stress, and inflammatory response - Increase autophagy flux - Chondrocytes from OA patients - Mouse chondrocytes Putrescine; Spermidine; Spermine - Reduces osteoclast activity - Increases bone volume and trabecular thickness of femur - Inhibition of muscle atrophy - Promotes the histological and ultrastructural integrity, and muscles strength The gut-bone axis represents a critical pathway in osteoporosis pathogenesis [73]. Within this axis, luminal polyamines exert anti-osteoporotic effects by promoting bone formation and inhibiting bone resorption [74]. Chevalier et al. demonstrated that warm ambient temperatures enhance the biosynthesis of polyamines by the gut microbiota. The resultant increase in systemic polyamine levels attenuates bone loss and improves bone strength. Mechanistically, polyamines upregulate the expression of osteopontin (OPN), osteoprotegerin (OPG), and RANKL to stimulate osteoblast activity, while simultaneously downregulating key osteoclast genes such as cathepsin K (CTSK), tartrate-resistant acid phosphatase (TRAP), and matrix metalloproteinase-9 (MMP9) to suppress osteoclast differentiation. Consistent with this, supplementation with SPD and SPM enhances skeletal strength in aged female mice. Conversely, inhibiting polyamine biosynthesis partially abrogates the bone-protective effects of a warm environment, underscoring the pivotal role of polyamines in this thermoregulatory pathway [64, 75]. Spermidine also confers protection against iron overload-induced bone metabolic disturbances. In rat models of iron overload, SPD activates the SIRT1/SOD2 signaling pathway, leading to a significant increase in bone mass, reduced reactive oxygen species (ROS) levels, and marked anti-osteoporotic effects. In vitro studies further confirm that SPD mitigates mitochondrial damage and alleviates oxidative stress in osteoblasts, while concurrently inhibiting osteoclast differentiation [76, 77]. Beyond SPD, polyamines broadly suppress osteoclastogenesis. Yeon et al. elucidated that polyamines inhibit the migration of osteoclast precursor cells via the Ca²⁺-PYK2-Src-NFATc1 signaling pathway, demonstrating potent anti-osteoclast activity [67]. Similarly, the polyamine metabolite 5’-methylthioadenosine (MTA) inhibits RANKL-induced NF-κB signaling and downregulates key osteoclastogenic transcription factors, including c-Fos and NFATc1, in a dose-dependent manner. Furthermore, MTA interferes with RANK receptor signaling, thereby restoring bone metabolic balance through suppression of the RANK-NFATc1 axis. These findings elucidate the molecular mechanism of MTA and highlight its therapeutic potential for osteoporosis [68]. Direct disruption of polyamine homeostasis, due to dysfunction of metabolic enzymes, can also lead to abnormal bone metabolism [78]. Snyder-Robinson syndrome (SRS), an X-linked disorder caused by loss-of-function mutations in the spermine synthase (SMS) gene, is characterized by intellectual disability, seizures, and severe osteoporosis. SMS deficiency results in SPD accumulation and SPM depletion, with the elevated SPD/SPM ratio positively correlating with clinical severity [42]. Detailed clinical and biochemical analyses of SRS patients confirm the osteoporotic phenotype. Correspondingly, studies in a novel SMS-mutant mouse model (SmsG56S/0) revealed significantly reduced trabecular bone volume, cortical thickness, and bone formation rates. Bone marrow-derived cells from these mice exhibited impaired mineralization capacity in vitro, demonstrating that SMS deficiency directly compromises osteoblast function. These findings establish SMS as essential for osteoblast activity and underscore the critical role of polyamine metabolism in bone remodeling [66]. Polyamines further influence the bone microenvironment by modulating oxidative stress and immune responses. Mature osteoclasts acidify the extracellular milieu via hydrogen ion release, facilitating bone matrix degradation by enzymes like CTSK and TRAP while concurrently generating reactive oxygen species (ROS) [79]. SPD counteracts this oxidative stress by enhancing antioxidant enzyme activity and reducing intracellular ROS levels, thereby alleviating associated cytotoxicity [80]. Inflammatory cytokines, including IL-1, IL-6, and TNF-α, exacerbate bone loss by stimulating osteoclast activity and impairing osteoblast function [81]. Polyamines exhibit anti-inflammatory properties, as evidenced by an inverse correlation between their levels and inflammation intensity. Polyamine depletion promotes pro-inflammatory M1 macrophage polarization, whereas polyamine enrichment fosters an immunosuppressive microenvironment through pathways involving arginase-1 (Arg1) [82]. Osteoarthritis Osteoarthritis (OA), a prevalent degenerative joint disease and a leading cause of age-related skeletal morbidity worldwide, imposes a substantial burden on the quality of life of the aging population [2, 83]. The pathological hallmarks of OA include progressive cartilage degradation, synovitis, and osteophyte formation, driven by a vicious cycle of chondrocyte metabolic imbalance, ECM degradation, and chronic low-grade inflammation [3, 84, 85]. Accumulating evidence underscores the pivotal contributions of cellular senescence and the senescence-associated secretory phenotype (SASP) to OA pathogenesis. Senescent chondrocytes secrete pro-inflammatory factors, including IL-6 and MMP-13, which activate the NF-κB signaling pathway. This activation, in turn, exacerbates ECM breakdown, suppresses the synthesis of key matrix components like collagen and aggrecan, and ultimately accelerates cartilage destruction [11]. Emerging insights into the “gut-joint axis” have further revealed a connection between gut microbiota composition and OA progression [86]. As metabolites abundantly present in the intestinal lumen and closely associated with microbial activity, polyamines have attracted increasing interest. However, their specific functions in chondrocyte senescence and the precise molecular mechanisms involved remain incompletely defined. Current evidence suggests that polyamines may modulate multiple signaling pathways, positioning them as potential therapeutic agents for osteoarthritis (Fig. 2). Schematic diagram of the mechanism by which spermidine regulates OA chondrocytes. Pro-inflammatory cytokines such as IL-1β and TNF-α exacerbate OA progression. SPD mitigates these pathological effects by modulating OA chondrocytes through key signaling pathways (NF-κB, STAT, and Nrf2), effectively reducing inflammatory responses. Additionally, SPD demonstrates dual chondroprotective actions by enhancing autophagic flux and suppressing pyroptosis in cartilage cells A clinical metabolomics study comparing OA patients with healthy controls identified significant correlations between polyamine metabolism and circulating levels of pro-inflammatory cytokines, such as TNF-α, IL-1β, and MIF, implying a potential immunomodulatory role for polyamines in OA [87]. Consistent with this, Chen et al. reported that intraperitoneal administration of SPD alleviated synovitis, cartilage degeneration, and osteophyte formation in mouse OA models, resulting in significantly improved OARSI scores. Mechanistically, SPD was shown to activate the deubiquitinase cylindromatosis (CYLD), which deubiquitinates receptor-interacting protein 1 (RIP1) and subsequently inhibits NF-κB/p65 signaling, thereby ameliorating OA pathology [58]. In another study, SPD exhibited anti-inflammatory and anti-pyroptotic effects in both rat anterior cruciate ligament transection (ACLT) models and chondrocyte inflammation models, primarily via engagement of the aryl hydrocarbon receptor (AhR). The binding of SPD to AhR concurrently suppressed the AhR/NF-κB and the NLRP3/caspase-1/GSDMD pathways, mitigating inflammation, pyroptosis, and ECM degradation [60]. Furthermore, Mao et al. discovered that SPD upregulates the chromatin remodeler BRG1, leading to activation of the Nrf2/KEAP1 pathway and inhibition of STAT3 phosphorylation in human chondrocytes and ACLT-induced mice. This dual action resulted in reduced inflammation and enhanced antioxidant capacity [61]. Beyond direct effects on chondrocytes, SPD also modulates the articular immune microenvironment by promoting a shift in macrophage polarization from the pro-inflammatory M1 to the anti-inflammatory M2 phenotype. This transition is mediated through inhibition of the ERK/MAPK and p65/NF-κB signaling pathways, thereby delaying OA progression [59, 88]. Autophagy, an evolutionarily conserved catabolic process in eukaryotic cells, is critical for maintaining cellular homeostasis, facilitating stress repair, and regulating growth and differentiation [89]. In the context of OA, autophagy activation mitigates chondrocyte inflammation, promotes mitochondrial repair, and helps preserve cartilage matrix integrity, thereby exerting protective effects. Conversely, autophagy deficiency accelerates both chondrocyte senescence and OA progression [90]. Supporting this, Sacitharan et al. observed markedly reduced autophagic activity and autophagosome formation in aged and osteoarthritic cartilage, evidenced by the downregulation of autophagy-related genes (e.g., ATG5, ATG7) and proteins (LC3-II, Beclin1), alongside reduced polyamine biosynthesis. Treatment with SPD enhanced the expression of the acetyltransferase EP300, which interacts with Beclin1 and LC3-II to potentiate chondrocyte autophagy, delay age-related cartilage degeneration, and reduce the secretion of pro-inflammatory factors [63]. In a complementary study, D’Adamo et al. demonstrated that SPD significantly increased Beclin-1 protein levels and elevated LC3-II and p62 mRNA/protein expression in primary human OA chondrocytes. Moreover, SPD reversed H₂O₂-induced impairment of autophagic flux, confirming its efficacy in activating autophagy and promoting chondrocyte proliferation. Together, these findings establish SPD’s chondroprotective role via autophagy restoration, oxidative stress suppression, and inflammation antagonism, highlighting novel avenues for targeted OA therapy [62]. Sarcopenia Sarcopenia is an age-related geriatric syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength [91]. Its co-occurrence with osteoporosis is termed osteosarcopenia, a condition that markedly exacerbates the risk of adverse clinical outcomes [92]. The progression of these conditions accelerates functional decline and mobility impairment, ultimately diminishing quality of life, increasing physical disability, and elevating the risk of falls, fractures, and premature mortality [93]. Pathogenetically, sarcopenia involves multifactorial mechanisms, including physical inactivity, chronic inflammation, oxidative stress, and impaired autophagy [94, 95]. Its global prevalence is conservatively estimated at 5–10%, though significant heterogeneity exists across diagnostic criteria and regions [96]. Proteomic studies have elucidated age-related muscle remodeling in the elderly, particularly a shift in fiber-type composition from fast-twitch type II to slow-twitch type I fibers [97]. Current therapeutic strategies aim to reverse or stabilize dynapenia to preserve physical function and quality of life; however, existing interventions such as resistance exercise and nutritional support show limited efficacy, and no pharmacotherapies are yet approved for clinical use [96]. Growing evidence links defective autophagy to sarcopenia pathogenesis. Reduced autophagic flux promotes the polarization of macrophages toward a pro-inflammatory M1 phenotype and enhances the secretion of cytokines that accelerate myocyte apoptosis [98, 99]. Notably, SPD and SPM, two endogenous polyamines, are recognized as natural autophagy inducers with demonstrated anti-aging properties and emerging roles in sarcopenia [100]. For instance, collagen VI-related myopathy is a hereditary disorder marked by muscle weakness, atrophy, and joint contractures. It is mechanistically linked to persistent AKT-mTOR activation and impaired autophagosome formation [101]. Chrisam et al. demonstrated that SPD supplementation reactivates autophagy in col6a1−/− mice, restoring muscle ultrastructure, improving strength, and attenuating atrophy. This effect is mediated through modulation of AKT-mTOR signaling and enhanced transcription of FOXO-dependent autophagy genes [70]. Satellite cells, situated between the basal lamina and the sarcolemma of muscle fibers, are essential for skeletal muscle maintenance and regeneration. Following muscle injury, these cells proliferate and differentiate to support myofiber repair [102]. While polyamines promote satellite cell activation and myogenesis in vitro, their effects in vivo are context-dependent. SPD administration in live models unexpectedly enhances autophagy specifically in satellite cells—without affecting myofiber autophagy—leading to muscle atrophy. This process involves EP300-mediated autophagy activation and suppression of the ACVR2B/Smads pathway in satellite cells, alongside increased protein ubiquitination in mature myofibers, collectively contributing to muscle degeneration [71]. These findings underscore the therapeutic potential of SPD as a satellite cell activator but also highlight the risk of adverse effects, including paradoxical muscle atrophy. The serum SPM/SPD ratio may serve as an indicative biomarker for sarcopenia. Sanayama et al. reported elevated serum SPD levels and a significantly reduced SPM/SPD ratio in sarcopenic patients, with the ratio inversely correlated with disease severity [72]. Similarly, a study of hemodialysis patients revealed markedly lowered SPM/SPD ratios that positively correlated with skeletal muscle mass index and handgrip strength. Based on these findings, the serum SPM/SPD ratio has emerged as a novel predictive biomarker for sarcopenia risk assessment [103]. Dysregulation of polyamine metabolism also contribute to osteosarcopenia via the androgen-polyamine axis. Hosoi et al. explored this link using fast-twitch muscle-specific androgen receptor knockout (fmARKO) mice. Male fmARKO animals exhibited substantial downregulation of key polyamine-metabolizing genes (e.g., AMD, ODC, and SMOX), accompanied by decreased SPM levels and significant reductions in both trabecular and cortical bone mineral density, indicative of osteosarcopenia predisposition. In contrast, female fmARKO mice exhibited no significant alterations in polyamine metabolic gene expression or BMD. Although the precise etiology underlying the BMD decline in male fmARKO mice remains unclear, these findings reveal a sexually dimorphic mechanism implicating the androgen-polyamine axis in the regulation of bone and muscle integrity [65]. Others Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent inflammation and a pronounced acceleration of immune system aging [104]. Early mechanistic studies identified an intrinsic upregulation of key polyamine-metabolizing enzymes, including AMD and SSAT in rheumatoid arthritis synovial fibroblasts (RASFs). Notably, SSAT overexpression was closely associated with genome-wide DNA hypomethylation, a hallmark of RASF activation. Subsequent intervention studies demonstrated that SSAT inhibition in murine models reduces RASF invasiveness, an effect mediated through the restoration of epigenetic regulation via enhanced DNA remethylation and elevated intracellular polyamine levels [105]. Further supporting the immunomodulatory role of polyamines in RA, CRISPR-Cas9–mediated knockdown of PTPN2 and PTPN22 in T-cell models markedly enhanced the secretion of pro-inflammatory cytokines such as IFN-γ and TNF-α. Treatment with 20µM SPD normalized cytokine expression and secretion, underscoring the capacity of polyamines to fine-tune inflammatory signaling in immune cells. These findings collectively highlight the therapeutic potential of polyamine-modulating strategies, including dietary supplementation, in the management of RA [106]. Periodontitis, a highly prevalent chronic inflammatory condition of oral tissues, is characterized by gingival bleeding, periodontal pocket formation, and progressive alveolar bone resorption. Affecting 70–90% of individuals aged 65 and older, it represents the primary cause of tooth loss in middle-aged and elderly populations worldwide [107]. Recent research has revealed that SPD exerts protective effects in periodontitis by activating mitophagy, a selective form of autophagy that clears damaged mitochondria. In human periodontal ligament stem cells (PDLSCs), SPD-induced mitophagy restores mitochondrial function, reactivates osteogenic differentiation capacity, and ameliorates cellular senescence. In diabetic periodontitis mouse models, SPD counteracts oxidative stress-induced depletion of Gli1+ stem cells and promotes periodontal tissue regeneration through the recruitment of Gli1+ PDLSCs. Mechanistically, SPD-activated mitophagy eliminates mitochondria with impaired membrane potential and associated oxidized DNA, thereby suppressing the activation of the cGAS–STING axis. This inhibition leads to reduced production of pro-inflammatory cytokines (e.g., IL-6, IFN-β) and senescence-associated secretory phenotype (SASP) factors, effectively disrupting the vicious inflammation–senescence feedback loop that drives disease progression [108]. Applications of polyamines in age-related bone diseases As research into polyamine metabolic pathways and their molecular mechanisms deepens, their critical roles in age-related bone disorders are being progressively unraveled. This growing body of evidence provides a solid theoretical foundation for identifying novel therapeutic targets. Notably, interventions targeting polyamine metabolism have demonstrated considerable promise in both in vitro and in vivo studies, highlighting the feasibility of developing innovative strategies for the prevention and treatment of age-related skeletal pathologies through the modulation of polyamine homeostasis. Polyamine supplementation therapy Exogenous polyamine supplementation has been shown to enhance osteogenic gene expression, alkaline phosphatase (ALP) activity, and matrix mineralization in human osteoblasts, while concurrently inhibiting osteoclastogenesis in murine monocytic RAW 264.7 cells. Consistent with these in vitro findings, ovariectomized rat models treated with exogenous polyamines exhibited a significant increase in bone mass [69, 109]. Jiang et al. further reported that SPM supplementation ameliorated osteoporosis in prednisolone-induced zebrafish models via a dual mechanism of promoting bone formation and suppressing bone resorption. The anti-osteoporotic effect of SPM is mediated through the Rac1-P53 axis. Importantly, SPM demonstrated excellent biocompatibility and attenuated prednisolone-induced embryonic neurotoxicity and cardiotoxicity, positioning it as a promising neuroprotective therapeutic candidate [110]. In a separate study, curcumin was found to improve osteoporosis by modulating the gut microbiota and serum metabolome. A key finding was that SPD levels negatively correlated with both inflammatory markers and osteoporosis severity, suggesting that the efficacy of curcumin may stem from its ability to reshape microbial composition and elevate beneficial serum metabolites, thereby optimizing the skeletal microenvironment [111]. In animal models of OA, exogenous SPD has also shown therapeutic potential. Ou et al. demonstrated that SPD supplementation protected against cartilage degradation in a murine destabilization of the medial meniscus (DMM) model. The treatment helped maintain articular cartilage integrity and synovial tissue homeostasis. Notably, conditioned medium from SPD-treated M1 macrophages significantly enhanced chondrocyte anabolism (e.g., promoting collagen production) while suppressing catabolism (e.g., reducing MMP expression) [59]. Similarly, in ACLT-induced mouse models, SPD administration upregulated antioxidant proteins (SOD, CAT) and chondrogenic genes (Col2a1, Acan), while effectively inhibiting pro-inflammatory cytokines such as IL-6 and TNF-α [61]. Beyond direct skeletal effects, studies have identified SPD as a key biochemical mediator of the benefits associated with caloric restriction and rapamycin treatment. Both rapamycin and fasting are known to extend lifespan and induce autophagy through mTOR and polyamine-dependent pathways. SPD acts as a biochemical surrogate for caloric restriction and a critical downstream effector of the anti-aging effects elicited by both fasting and rapamycin [112–114]. Supporting this role, a two-week supplementation of SPD in aged mice reversed age-related defects in autophagy and mitophagy within muscle stem cells, promoting muscle regeneration and ameliorating sarcopenia [115]. Modulation of polyamine metabolic enzymes Targeting key enzymes in polyamine metabolism represents a promising therapeutic strategy for age-related bone disorders. Among them, DFMO, a specific inhibitor of ODC—the rate-limiting enzyme in polyamine biosynthesis—has shown potential in modulating bone metabolism. Stewart et al. systematically evaluated the translational applicability of DFMO for treating osteoporosis in Snyder-Robinson syndrome (SRS), a condition caused by spermine synthase (SMS) deficiency. Their findings revealed that DFMO exerts a dual regulatory effect on polyamine metabolism: it not only suppresses SPD biosynthesis but also promotes the conversion of SPD to SPM in cells with low SMS activity. This action, combined with enhanced uptake of exogenous SPM, effectively normalizes the pathological SPD/SPM ratio. In Drosophila models of SRS, DFMO treatment significantly rescued the reduced lifespan caused by SMS deficiency. Given that more than 90% of SRS patients carry hypomorphic SMS mutations, this study establishes a critical theoretical foundation in translational medicine for SRS-related osteoporosis [42]. In a related study, excess polyamines—particularly SPD—were found to markedly impair the hydroxyapatite synthesis capacity of primary BMSCs, whereas DFMO-mediated inhibition of polyamine synthesis rescued most of the mineralization defects [116]. These collective findings position DFMO as a promising candidate for ameliorating dysregulated bone metabolism in SRS. Therapeutic strategies targeting SSAT, the key enzyme in polyamine catabolism, have also demonstrated efficacy across multiple age-related bone diseases. Cressman et al. observed that while mRNA levels of most polyamine-related enzymes remained stable during osteogenic differentiation, SSAT expression was uniquely and significantly upregulated at both the mRNA and protein levels [116]. In the context of osteoarthritis, Xu et al. reported that SSAT inhibition downregulated Alox15 expression and activated the Nrf2 antioxidant pathway, thereby significantly alleviating ferroptosis and inflammatory responses in chondrocytes and delaying OA progression [117]. Similarly, in an osteoporosis mouse model, treatment with the SSAT inhibitor Berenil promoted osteoclast apoptosis and reversed bone loss, demonstrating its potential as a clinical treatment strategy for osteoporosis [118]. Balancing the SPM/SPD ratio The SPM/SPD ratio is a critical determinant of cellular homeostasis, with its imbalance being closely implicated in the pathogenesis of human diseases such as Snyder-Robinson syndrome (SRS) and sarcopenia. An appropriate SPM/SPD ratio is essential for the regulation of autophagy—a process vital for the growth, differentiation and function of cell communities within the bone microenvironment. Through modulating autophagic activity, the SPM/SPD ratio influences the metabolic behaviors of osteoblasts and osteoclasts, thereby exerting a profound impact on bone remodeling and overall skeletal homeostasis [119–121]. Supporting this concept, a study using yeast-fermented garlic (YF) extract revealed that a specific SPM/SPD ratio, rather than the absolute concentration of either polyamine alone, is responsible for inducing autophagic flux. Treatment of HAP1 cells with SPD or SPM individually at concentrations equivalent to their content in YF failed to enhance autophagy. In contrast, administering a combination of SPD and SPM that recapitulated the ratio found in YF successfully increased autophagic flux [122]. This finding underscores that the balance between these polyamines, rather than their isolated abundance, is a key regulator of autophagic activity. Therefore, maintaining a balanced SPM/SPD ratio represents a promising therapeutic avenue for preserving cellular homeostasis through the fine-tuning of autophagy. Given that polyamines are endogenous, naturally occurring autophagy inducers with low toxicity, strategies aimed at modulating their ratio hold substantial potential for broader application in the treatment of other human diseases characterized by autophagic dysfunction. Combined application of medical biomaterials Medical biomaterials, which integrate excellent biocompatibility with tunable physicochemical properties, are increasingly applied in regenerative medicine and disease treatment. Leveraging the bioactivity of polyamines, several advanced material systems have been developed to enhance bone and periodontal regeneration. Cheon et al. developed an injectable, single-component hydrogel based on SPD-conjugated phenylboronic acid-modified hyaluronic acid. This formulation undergoes spontaneous “self-curing” after injection, forming a stable hydrogel scaffold in situ. When loaded with human mesenchymal stem cells (hMSCs) and implanted into a rat femoral defect model, the SPD-functionalized hydrogel effectively supported cell proliferation and induced robust osteogenic differentiation and mineralization, leading to significant bone regeneration [123]. In a related approach, a dual-network hydrogel system was constructed from Pluronic F127 (PF-127) and hyaluronic acid methacrylate (HAMA), incorporating SPD-modified mesoporous polydopamine nanoparticles. This platform combined injectability, thermosensitivity, and photocrosslinking capability, allowing it to conform precisely to the irregular contours of periodontal pockets. Under pro-inflammatory conditions simulated by LPS-stimulated macrophage-conditioned medium, the hydrogel (denoted PH/M@S) restored the osteogenic differentiation capacity of cells by rescuing BMP-2 and RUNX2 expression. In a rat periodontitis model, local application of the hydrogel reduced alveolar bone resorption by 63.7% and significantly decreased IL-1β levels in gingival crevice fluid [124]. In addition to soft hydrogels, Ren et al. engineered a titanium implant material with a porous N-halamine-based polymeric coating containing spermidine (Ti-SPD-Cl), which demonstrated simultaneous antibacterial and osteogenic properties. The Ti-SPD-Cl surface was rich in N-Cl active groups, endowing it with potent bactericidal activity against Staphylococcus aureus and Escherichia coli. Owing to the synergistic effect of the incorporated SPD and the porous hydrophilic surface, the material promoted cell adhesion and osteogenic activity while maintaining membrane homeostasis. In a rat osteomyelitis model, Ti-SPD-Cl effectively prevented bacterial infection and enhanced bone-implant integration, highlighting its clinical potential for improving the success of orthopedic implants [125]. Summary and outlook Polyamines are versatile, low-molecular-weight cations that play integral roles in a multitude of fundamental physiological processes, with growing evidence underscoring their significant impact on skeletal health [17]. Current evidence indicates that polyamines modulate bone metabolism through multifaceted mechanisms, including the regulation of the immune microenvironment, inflammatory responses, and oxidative stress, thereby affecting the progression of age-related bone diseases. Singh et al. established a fluorescence-based assay to quantify aminopropyl transferase activity in polyamine biosynthesis, offering a valuable platform for high-throughput drug screening against bone diseases [26]. These insights open new avenues for exploring the molecular basis of skeletal aging and for developing innovative therapeutic strategies [126]. However, as research on polyamines advances, several challenges have emerged. First, the biological functions of polyamines in bone are highly complex, involving the regulation of cell proliferation, differentiation, and apoptosis across various bone cell types. This functional pleiotropy necessitates a more systematic, multi-omics approach to decipher their cell-type-specific roles in bone homeostasis and to identify the core molecular nodes that could be targeted therapeutically [127]. Second, while polyamines show clear modulatory potential in preclinical models, their clinical efficacy and long-term safety profiles remain to be firmly established. For instance, SPD exhibits a dual role: it mitigates oxidative stress by reducing general ROS levels, yet in excess, it can paradoxically promote the generation of superoxide radicals, leading to cytotoxic effects [128]. Moreover, as demonstrated in Saccharomyces cerevisiae, SPD toxicity can be linked to deficiencies in mitochondrial complex III, suggesting that individual genetic or metabolic variations may predispose certain populations to adverse, rather than beneficial, outcomes [129]. This underscores the necessity for patient stratification in future clinical applications. In conclusion, polyamines represent a promising class of endogenous molecules with considerable therapeutic potential for the management of age-related bone disorders. To bridge the gap between bench and bedside, future efforts should focus on: (1) Elucidating the key signaling pathways and downstream effectors through which polyamines exert their effects on osteoblasts, osteoclasts, and chondrocytes; (2) Developing targeted therapeutic strategies, including the modulation of polyamine-metabolizing enzymes, the use of novel polyamine analogs, and the engineering of polyamine-functionalized biomaterials; and (3) Conducting rigorous, well-controlled preclinical studies and subsequent clinical trials to definitively validate the therapeutic utility and safety of polyamine-based interventions. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 (DOCX 270 KB) Acknowledgements The authors have nothing to report. Author contributions J.Q.Z., C.C., and Y.F.Z. contributed equally to this work. J.Q.Z. and C.C. provided direction and guidance throughout the preparation of this manuscript. J.Q.Z., C.C., Y.F.Z. and J.L., wrote and edited the manuscript. C.L., S.C.H., K.W., C.G.S., and G.H.X. reviewed and made significant revisions to the manuscript. J.Q.Z., and J.L. revised and edited the manuscript. All authors read and approved the final manuscript. Funding This work was supported by the National Natural Science Foundation of China (NOs. 81972076 and 82272533). Data availability Not applicable. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no conflicts of interest. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Changgui Shi, Email: charlieshi@smmu.edu.cn. Jia Liu, Email: 13506191593@163.com. Guohua Xu, Email: xuguohuamail@163.com. References Associated Data Supplementary Materials Supplementary Material 1 (DOCX 270 KB) Data Availability Statement Not applicable.